About Event
Welcome to the 4th Annual CRISPR 2.0 Congress
Across 3 days of keynote plenaries, new data readouts, and focused group discussions, attendees heard from and engaged with the likes of CRISPR Therapeutics, Editas Medicine, Caribou Biosciences, Prime Medicine, the Doudna Lab, and 70+ other leading drug developers, academic institutes, and leading service providers.
Enabling in-depth presentations and focused group discussions, for the first time this year, CRISPR 2.0 had 2 dedicated tracks of content:
- Technology Innovation: Showcasing the most innovative discovery, R&D, and platforms from 2023
- Translating to the Clinic: Levelling up strategy to progress through late preclinical, IND, and early clinical stages
As well as leveraging insights from these talks and panels – attendees engaged in stimulating discussions, hands-on workshops, and leveraged 7+ hours of networking opportunities with their peers to foster collaboration and spark ground-breaking ideas.
This summit brought together the hottest voices in the field to:
Outline the Latest & Greatest Technology Platforms
Uncover progress being made with integrase-based large sequence insertion, explore the latest developments with novel nucleases, and understand how epigenetic editing is revolutionizing genetic medicine, with insights from Tune Therapeutics and the AbuGoot Lab
Leverage Strategic Insights to Progress into the Clinic
Level up the efficiency and safety of your CRISPR therapy, improve your IND clearance strategy, and apply learnings from clinical leaders in the field, with Excision BioTherapeutics and Beam Therapeutics
Optimize your Delivery Platform
Understand how novel, non-viral delivery methods are being developed for in vivo tissue-targeting, and explore the next-generation evolution of more established delivery vehicles, with Life Edit Therapeutics and Sanofi
Assess, Monitor, & Predict Off-Target Edits
How should you approach guide purity characterization? How can you analyze off-target effects of new CRISPR tools? What are the functional consequences of observed off-target edits? Editas Medicine and ToolGen answered these questions and many more
Overcome the CRISPR Licensing Challenge
Better understand the CRISPR patent dispute landscape, navigate the timeframes associated with sourcing licenses, and collectively discuss where the field needs to progress to unpick the complexities of intellectual property, with discussions led by the University of Kansas School of Law
“The audience was engaged and asked great questions. The networking was also excellent” – eGenesis Bio
“I'm optimistic these companies will play a big part in fulfilling the promise of CRISPR to treat the underlying genetic cause of human diseases” – Scribe Therapeutics